Contribution of matrix metalloproteinases-1 genotypes to gastric cancer susceptibility in Taiwan

Abstract

Expression of matrix metalloproteinase-1 (MMP1), an interstitial collagenase regulating the extracellular matrix, plays a major role in carcinogenesis of gastric cancer, a leading cause of death worldwide. In literature, the single-nucleotide polymorphism (SNP) promoter -1607 1G/2G (rs1799750) at the MMP1 gene promoter has been reported to alter its own transcription level. While the importance’s of the genotype of MMP1 promoter -1607 has not yet been studied in gastric cancer in Taiwan, our aim was to investigate MMP1 promoter -1607 genotypes and gastric cancer (GC) susceptibility in central Taiwan population. In the current hospital-based case-control study, the contribution of MMP1 promoter -1607 genotypes to GC risk was investigated among 121 GC patients and 363 gender- and age-matched healthy controls recruited and genotyped by the polymerase chain reaction-based restriction fragment length polymorphism (PCR-RFLP) methodology. We found that the genotypic and allelic frequencies were not differentially distributed between GC patient and control groups. The variant 1G containing genotypes have interactions with cigarrete smoking behaviors and Helicobacter pylori infection status, but not alcoholism on GC susceptibility determination. Our findings suggest that the variant 1G allele on MMP1 promoter -1607 may contribute to GC carcinogenesis and may be useful for GC early detection and prevention when combined with cigarrete smoking behaviors and Helicobacter pylori infection status.

Soya-cerebroside reduces IL-1β-induced MMP-1 production in chondrocytes and inhibits cartilage degradation: implications for the treatment of osteoarthritis

“…It is well accepted, however, that cartilage degradation is a critical step during OA development. Dysregulated MMP activity is obvious in several pathological conditions associated with loss of normal collagen architecture (Yang et al, 2017). Researchers have therefore proposed that therapeutic strategies should target MMPs in the treatment of arthritis (Troeberg & Nagase, 2012;Wang, Xu, Hunter, & Ding, 2015).…”

Glucose suppresses IL‐1β‐induced MMP‐1 expression through the FAK, MEK, ERK, and AP‐1 signaling pathways

“…35,36 In this study, we found that a FAK inhibitor, MEK inhibitors Cytokines, chemokines, and growth factors are known to regulate gene expression through the AP-1 site. 37,38 It has been reported that saponins reduce MMP-1 expression in immortalized human keratinocytes (HaCaT) via AP-1-dependent signaling 39 and that luteolin suppresses IL-1β-induced MMP production by inhibiting AP-1 activation. 40 In this study, AP-1 inhibitors and siRNA reduced IL-1β-induced MMP-1 expression, suggesting that AP-1 activation mediates IL-1β-increased MMP-1 expression.…”

The association between MMP-1 gene rs1799750 polymorphism and knee osteoarthritis risk

“…Rech et al [ 20 ] uncovered that MMP-1 gene variants were associated with systemic sclerosis. A host of studies also demonstrated that MMP-1 gene rs1799750 polymorphism was related to cancer susceptibility, such as leukemia [ 21 ] and gastric cancer [ 22 ]. We assumed that rs1799750 polymorphism mediated the MMP-1 expression, thereby contributing to the risk for many diseases, which needs further studies to verify it.…”